Related Experiment Video
Updated: May 27, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Polymorphisms in immune function genes and non-Hodgkin lymphoma survival
Briseis Aschebrook-Kilfoy1, Tongzhang Zheng, Francine Foss
1School of Public Health, Yale University, New Haven, CT, USA. kilfoyb@mail.nih.gov
Journal of Cancer Survivorship : Research and Practice
|November 25, 2011
Summary
Genetic variations in cytokine genes, particularly IL6, impact non-Hodgkin lymphoma (NHL) survival. Identifying these polymorphisms can improve NHL prognosis prediction.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- Cytokines are crucial regulators of the immune system.
- In the tumor microenvironment, cytokines affect cell behavior and tumor interactions.
- Cytokine activity is hypothesized to influence non-Hodgkin lymphoma (NHL) pathogenesis.
Purpose of the Study:
- To investigate the impact of genetic variations in cytokine genes on NHL prognosis and survival.
- To evaluate the combined effects of multiple deleterious genotypes on NHL outcomes.
Main Methods:
- Survival data from 496 female NHL cases (1996-2000) were analyzed.
- Genetic variations in single nucleotide polymorphisms (SNPs) and combined genotypes were assessed.
- Cox proportional hazard models were used to compute hazard ratios (HR), adjusting for covariates.
Main Results:
- The variant IL6 genotype was significantly associated with a decreased risk of death, relapse, and secondary cancers (HR=0.42).
- Risk of death, relapse, and secondary cancers varied by specific SNPs across NHL histologic types (follicular, DLBCL, CLL/SLL).
- Combinations of polymorphisms significantly altered overall and disease-free survival in NHL patients.
Conclusions:
- Genetic polymorphisms in cytokine genes can help predict NHL survival.
- Identifying specific genetic variations may improve prognostic accuracy for NHL patients.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...